Full text

Turn on search term navigation

© 2021. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

We conducted a prospective multicenter trial to compare the usefulness of 11C‐methionine (MET) and 18F‐fluorodeoxyglucose (FDG) positron emission tomography (PET) for identifying tumor recurrence. Patients with clinically suspected tumor recurrence after radiotherapy underwent both 11C‐MET and 18F‐FDG PET. When a lesion showed a visually detected uptake of either tracer, it was surgically resected for histopathological analysis. Patients with a lesion negative to both tracers were revaluated by magnetic resonance imaging (MRI) at 3 months after the PET studies. The primary outcome measure was the sensitivity of each tracer in cases with histopathologically confirmed recurrence, as determined by the McNemar test. Sixty‐one cases were enrolled, and 56 cases could be evaluated. The 38 cases where the lesions showed uptake of either 11C‐MET or 18F‐FDG underwent surgery; 32 of these cases were confirmed to be subject to recurrence. Eighteen cases where the lesions showed uptake of neither tracer received follow‐up MRI; the lesion size increased in one of these cases. Among the cases with histologically confirmed recurrence, the sensitivities of 11C‐MET PET and 18F‐FDG PET were 0.97 (32/33, 95% confidence interval [CI]: 0.85‐0.99) and 0.48 (16/33, 95% CI: 0.33‐0.65), respectively, and the difference was statistically significant (P < .0001). The diagnostic accuracy of 11C‐MET PET was significantly better than that of 18F‐FDG PET (87.5% vs. 69.6%, P = .033). No examination‐related adverse events were observed. The results of the study demonstrated that 11C‐MET PET was superior to 18F‐FDG PET for discriminating between tumor recurrence and radiation‐induced necrosis.

Details

Title
Determination of brain tumor recurrence using 11C‐methionine positron emission tomography after radiotherapy
Author
Yamaguchi, Shigeru 1   VIAFID ORCID Logo  ; Hirata, Kenji 2 ; Okamoto, Michinari 1 ; Shimosegawa, Eku 3 ; Hatazawa, Jun 4 ; Hirayama, Ryuichi 5 ; Kagawa, Naoki 5 ; Kishima, Haruhiko 5 ; Oriuchi, Noboru 6 ; Fujii, Masazumi 7 ; Kobayashi, Kentaro 8 ; Kobayashi, Hiroyuki 1 ; Terasaka, Shunsuke 1 ; Ken‐ichi Nishijima 9 ; Kuge, Yuji 10 ; Ito, Yoichi M 11 ; Nishihara, Hiroshi 12 ; Nagara Tamaki 13 ; Shiga, Tohru 14 

 Department of Neurosurgery, Faculty of Medicine, Hokkaido University, Sapporo, Japan 
 Department of Nuclear Medicine, Hokkaido University Hospital, Sapporo, Japan; Department of Diagnostic Imaging, Graduate School of Medicine, Hokkaido University, Sapporo, Japan 
 Department of Molecular Imaging in Medicine, Graduate School of Medicine, Osaka University, Suita, Japan 
 Research Center for Nuclear Physics, Osaka University, Suita, Japan 
 Department of Neurosurgery, Graduate School of Medicine, Osaka University, Suita, Japan 
 Department of Nuclear Medicine, Fukushima Medical University Hospital, Fukushima, Japan; Advanced Clinical Research Center, Fukushima Global Medical Science Center, Fukushima Medical University, Fukushima, Japan 
 Department of Neurosurgery, Fukushima Medical University, Fukushima, Japan 
 Department of Diagnostic Imaging, Graduate School of Medicine, Hokkaido University, Sapporo, Japan 
 Advanced Clinical Research Center, Fukushima Global Medical Science Center, Fukushima Medical University, Fukushima, Japan; Central Institute of Isotope Science, Hokkaido University, Sapporo, Japan 
10  Central Institute of Isotope Science, Hokkaido University, Sapporo, Japan 
11  Biostatistics Division, Clinical Research and Medical Innovation Center, Hokkaido University Hospital, Sapporo, Japan 
12  Genomics Unit, Keio Cancer Center, Keio University School of Medicine, Tokyo, Japan 
13  Department of Nuclear Medicine, Hokkaido University Hospital, Sapporo, Japan; Department of Radiology, Kyoto Prefectural University of Medicine, Kyoto, Japan 
14  Department of Nuclear Medicine, Hokkaido University Hospital, Sapporo, Japan; Department of Nuclear Medicine, Fukushima Medical University Hospital, Fukushima, Japan; Advanced Clinical Research Center, Fukushima Global Medical Science Center, Fukushima Medical University, Fukushima, Japan 
Pages
4246-4256
Section
ORIGINAL ARTICLES
Publication year
2021
Publication date
Oct 2021
Publisher
John Wiley & Sons, Inc.
ISSN
13479032
e-ISSN
13497006
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2578178334
Copyright
© 2021. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.